Vascular complications in adult patients with COVID- 19 infection in Margan Hospital, Babylon Governorate, Iraq: (January of 2020 to June of 2021)
Keywords:
COVID-19 infection, study, vascular, complications, comorbidityAbstract
This study has been performed for assessment of clinical course and risk factors for vascular thrombotic events in adult inpatients with coronavirus 2019 infection (COVID-19). This infection has become a serious global challenge affect large number of populations worldwide lead to significant morbidity and mortality specially from vascular disorders. Our study included 900 patients admitted to Margan hospital in Babylon Governorate, Iraq from January of 2020 to June of 2021. 551 (61.2%) was male and 349 (38.8%) was female. Fifty-eight (6.5%) of all patients had vascular complication of different forms. The most frequent type of vascular complications was cerebrovascular accidents involved 23 patients (39.7%) and other types include coronary artery diseases, peripheral vascular diseases and deep venous thrombosis. The mean age of the affected patients with vascular complications was (64 years) while for patients with no vascular complications was (53.17 years). The most frequent associated symptom in affected patients is chest pain (N=15, 25.9%), other symptoms include disturb level of consciousness, lower limb pain, lower limb swelling, side body weakness and shortness of breath. For all 58 patients, the mean SPO2% on admission was 89% and mean of lowest SPO2% was 80%. In this study we perform comparison in certain variables between affected group with vascular complication(N=58) and other non-affected group and this comparison showed that (58.6%) of affected group were smoker and 72.4% with comorbidity while just (5.3%) of non-affected group were smoker and 43.2% with comorbidity, the mean lung involvement by Chest CT-scan was 62% for affected patients group and 45% for other, C-reactive protein(CRP) was positive in 86.2% of affected group and 65.8% of non-affected group. Only 166(18.4%) of 900 patients had died [18% of them with vascular complications] while the majority of patients (707) (78.6%) get complete cure [only 1.5% of them with vascular complications].
According to this study our findings demonstrate that:
- Smoking, older age and presence of comorbidity increase risk of vascular complications in patients with COVID-19 infection.
- In cases of COVID-19 infection, the positive CRP and lung involvement (by CT scan of chest) is significantly more in patient with vascular complications.
- Vascular complications is significantly present more in died patients in this study than in cure patients, so this can make the vascular disorders an important mortality factor.
Downloads
References
Andersen, K.G., Rambaut, A., Lipkin, W.I., Holmes, E.C., & Garry, R.F. (2020). *The proximal origin of SARS-CoV-2*. Nature Medicine, 26(4), 450-452. [https://doi.org/10.1038/s41591-020-0820-9](https://doi.org/10.1038/s41591-020-0820-9)
Bangalore, S., Sharma, A., Slotwiner, A., Yatskar, L., Harari, R., et al. (2020). *ST-Segment Elevation in Patients with Covid-19 - A Case Series*. The New England Journal of Medicine, 382(25), 2478-2480. [https://doi.org/10.1056/nejmc2009020](https://doi.org/10.1056/nejmc2009020)
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., et al. (2020). *Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study*. The Lancet, 395(10223), 507-513. [https://doi.org/10.1016/s0140-6736(20)30211-7](https://doi.org/10.1016/s0140-6736(20)30211-7)
Goshua, G., Pine, A.B., Meizlish, M.L., Chang, C.H., Zhang, H., et al. (2020). *Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study*. The Lancet Haematology, 7(8), e575-e582. [https://doi.org/10.1016/s2352-3026(20)30216-7](https://doi.org/10.1016/s2352-3026(20)30216-7)
Klok, F.A., Kruip, M., van der Meer, N.J.M., Arbous, M.S., Gommers, D., et al. (2020). *Incidence of thrombotic complications in critically ill ICU patients with COVID-19*. Thrombosis Research, 191, 145-147. [https://doi.org/10.1016/j.thromres.2020.04.013](https://doi.org/10.1016/j.thromres.2020.04.013)
Libby, P., Loscalzo, J., Ridker, P.M., Farkouh, M.E., Hsue, P.Y., et al. (2018). *Inflammation, Immunity, and Infection in Atherothrombosis: JACC Review Topic of the Week*. Journal of the American College of Cardiology, 72(17), 2071-2081. [https://doi.org/10.1016/j.jacc.2018.08.1043](https://doi.org/10.1016/j.jacc.2018.08.1043)
Nao, N., Yamagishi, J., Miyamoto, H., Igarashi, M., Manzoor, R., et al. (2017). *Genetic Predisposition To Acquire a Polybasic Cleavage Site for Highly Pathogenic Avian Influenza Virus Hemagglutinin*. mBio, 8(1), e02298-02216. [https://doi.org/10.1128/mbio.02298-16](https://doi.org/10.1128/mbio.02298-16)
Osterud, B., Bajaj, M.S., & Bajaj, S.P. (1995). *Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions*. Thrombosis and Haemostasis, 73(5), 873-875. URL: [https://pubmed.ncbi.nlm.nih.gov/7482419/](https://pubmed.ncbi.nlm.nih.gov/7482419/)
Tang, N., Li, D., Wang, X., & Sun, Z. (2020). *Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia*. Journal of Thrombosis and Haemostasis, 18(4), 844-847. [https://doi.org/10.1111/jth.14768](https://doi.org/10.1111/jth.14768)
Tavazzi, G., Pellegrini, C., Maurelli, M., Belliato, M., Sciutti, F., et al. (2020). *Myocardial localization of coronavirus in COVID-19 cardiogenic shock*. European Journal of Heart Failure, 22(5), 911-915. [https://doi.org/10.1002/ejhf.1828](https://doi.org/10.1002/ejhf.1828)
van Hinsbergh, V.W. (2012). *Endothelium--role in regulation of coagulation and inflammation*. Seminars in Immunopathology, 34(1), 93-106. [https://doi.org/10.1007/s00281-011-0285-5](https://doi.org/10.1007/s00281-011-0285-5)
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., et al. (2020). *Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China*. JAMA, 323(11), 1061-1069. [https://doi.org/10.1001/jama.2020.1585](https://doi.org/10.1001/jama.2020.1585)
White, T.A., Johnson, T., Zarzhevsky, N., Tom, C., Delacroix, S., et al. (2010). *Endothelial-derived tissue factor pathway inhibitor regulates arterial thrombosis but is not required for development or hemostasis*. Blood, 116(10), 1787-1794. [https://doi.org/10.1182/blood-2009-10-250910](https://doi.org/10.1182/blood-2009-10-250910)
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., et al. (2020). *A Novel Coronavirus from Patients with Pneumonia in China, 2019*. The New England Journal of Medicine, 382(8), 727-733. [https://doi.org/10.1056/nejmoa2001017](https://doi.org/10.1056/nejmoa2001017)
Downloads
Published
Issue
Section
License
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
